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Abstract
Background and Purpose: To investigate combining unmodulated electron beams with intensity-modulated
radiation therapy to improve dose distributions for superficial head and neck cancers, and to compare mixed beam
plans with helical tomotherapy.
Materials and methods: Mixed beam and helical tomotherapy dose plans were developed for two patients with
parotid gland tumors and two patients with nasal cavity tumors. Mixed beam plans consisted of various
weightings of a enface electron beam and IMRT, which was optimized after calculation of the electron dose to
compensate for heterogeneity in the electron dose distribution within the target volume.
Results: Helical tomotherapy plans showed dose conformity and homogeneity in the target volume that was
equal to or better than the mixed beam plans. Electron-only plans tended to show the lowest doses to normal
tissues, but with markedly worse dose conformity and homogeneity than in the other plans. However, adding a
20% IMRT dose fraction (i.e., IMRT:electron weighting = 1:4) to the electron plan restored target conformity and
homogeneity to values comparable to helical tomotherapy plans, while maintaining lower normal tissue dose.
Conclusions: Mixed beam treatments offer some dosimetric advantages over IMRT or helical tomotherapy for
target depths that do not exceed the useful range of the electron beam. Adding a small IMRT component (e.g.,
IMRT:electron weighting = 1:4) to electron beam plans markedly improved target dose homogeneity and
conformity for the cases examined in this study.
Keywords: electron beam therapy, intensity modulated radiation therapy, helical tomotherapy, mixed beam ther-
apy, head and neck cancer
I. Introduction
Clinical radiation therapy techniques for superficial (i.e.,
located within approximately 5 cm of the patient sur-
face) head and neck cancers have evolved dramatically
over the past several decades. Historically, superficial
head and neck targets were treated with wedged pairs of
photons, orthovoltage x-rays, or electron beams often
mixed with photons [1]. Introduction of the modern
photon multileaf collimator (MLC) enabled intensity
modulated delivery techniques that improved dose con-
formity and homogeneity compared to electron and
conventional mixed techniques [2], resulting in better
tumor control and lower normal tissue complication
probabilities. A more recent development is helical
tomotherapy, where intensity modulation is achieved by
translating the patient through a rotating gantry on
which a linear accelerator head and binary MLC are
mounted [3].
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apy for superficial cancers generally conclude that it is
capable of delivering dose distributions that are equiva-
lent to or better than distributions delivered with fixed-
beam IMRT [4,5] These results, augmented with institu-
tional experience, have resulted in helical tomotherapy
often being the treatment of choice for head and neck
cancer in our clinic.
A number of groups have reported dosimetric results
from intensity- and energy- modulated electron beams
using either a commercial photon [6-9] or custom elec-
tron [10-12] MLC. For example, Salguero et al. [8]
reported that modulated electron radiation therapy
plans created with a photon MLC showed comparable
target volume dose homogeneity and significantly lower
normal tissue dose compared with fixed-beam IMRT
plans in four patients with superficial tumors head and
neck tumors. Ma et al. [13] concluded that modulated
electron therapy could achieve superior dose conformity
for superficial breast cancer compared with IMRT.
However, those studies required either custom hardware
(in the case of electron MLC) and/or custom treatment
planning systems (typically configured with Monte Carlo
simulation capabilities) that are not widely available.
Other studies have reported on combining unmodulated
electron beams with IMRT to improve dose distribu-
tions for head and neck cancers. Mu et al. [14] com-
pared various mixtures of electrons and IMRT for five
deep-seated head and neck targets. They reported that
the mixed beam plans achieved adequate target and nor-
mal tissue dose with lower integral dose, and concluded
that mixed beam plans could more readily meet plan-
ning goals if computerized optimization tools were avail-
able. Their study was limited in that (1) some or all of
the selected target structures typically exceeded the use-
ful range of electron beams and (2) inverse planning of
the IMRT fields did not include dose contributions from
the electron beams. More recently, Chan et al. reported
that combining electrons and IMRT improved target
dose homogeneity and decreased normal tissue dose for
patients with extensive scalp lesions [15] and mesothe-
lioma [16] compared with IMRT alone.
The motivation for this study was (1) to assess the uti-
lity of combining unmodulated electron beams with
IMRT for patients with disease that could best exploit
the advantages of electron beams, and (2) to determine
the optimal beam weighting when IMRT fields are
allowed to optimize with the electron beam dose taken
into account. Our objective was to investigate mixed
beam plans for treating superficial cancers of the parotid
gland and nasal cavity, and to compare these plans with
those developed with our current clinical standard of
care for head and neck cancer, helical tomotherapy.
II. Methods and materials
II.A. Patients
Four patients previously treated at our institution for
superficial head and neck cancers were selected and
placed into a Health Insurance Portability and Account-
ability-compliant database. The criteria for patient selec-
tion was (1) that the primary planning target volume
(PTV) did not extend beyond the therapeutic range of a
20 MeV electron beam (approximately 5.5 cm in tissue)
(2) the availability of three-dimensional computed tomo-
graphy data suitable for treatment planning and (3) the
patient had been previously treated with IMRT or
TomoTherapy. Final patient selection was determined
by the physician on the basis of clinical interest in site
that stood to benefit most from mixed beam treatments.
Disease pathology, staging (where available), location,
patient gender, and patient age for the patients selected
for this work are shown in Table 1. Helical tomotherapy
and mixed beam treatment plans were developed for
these patients and compared.
II.B. Treatment planning
PTVs and OARs/prescriptions
Organ-at-risk (OAR) volumes were contoured for each
each patient. Most OARs were generated by either the
physician or the dosimetrist (evaluated and modified by
the physician if necessary) in the original plan. The
OARs previously contoured for the parotid patients
were the contralateral parotid, eyes, lenses, optic nerve,
and spinal cord. The OARs previously contoured for the
nasal cavity patients were the spinal cord, eyes, lenses,
and optic nerves.
For the parotid gland tumors, in order to provide a
build-up of dose to the PTV near the skin surface or
to surgical scars in these post-operative patients, a tis-
sue-equivalent bolus was contoured. The bolus also
served to compensate for missing tissue, around the
ear. The bolus for the parotid patients was either con-
toured as a 0.5 cm or 1.0 cm thick (depending on the
depth of PTV, energy of electron beam, and OAR dis-
t a lt ot h eP T V )e x p a n s i o nt ot h es k i n .B o l u sw a sa l s o
used for the nasal cavity tumors to minimize the
impact of surface irregularities on the electron dose.
For these patients, the bolus was fabricated during
simulation such that an enface electron beam would
impinge upon a flat surface.
Once all the contours and dose limiting structures
were defined, pre-optimization plan parameters values
were set. The prescription and planning goals in the
helical tomotherapy and mixed beams plans were kept
as close as the differences in the systems would allow.
Dose prescriptions for the parotid gland tumors were
59.4 Gy and 65.0 Gy for patients 1 and 2, respectively;
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patients 3 and 4, respectively.
Mixed Beam Planning
Mixed beam plans were constructed using the Philips
Pinnacle
3 (8.1×, Philips Medical Systems, Fitchburg, WI)
treatment planning system with corrections for patient
heterogeneities. Mixed beam plans were designed as a
combination of a five (nasal cavity patients) or seven
(parotid gland patients) field 6-MV IMRT plan opti-
m i z e do nt o po fas i n g l ee n f a c e1 6M e Vo r2 0M e V
electron beam. For all patients, the enface electron
beam was oriented normal to the patient plane and
blocked to a 1 cm margin around the PTV. A 1.0 cm
thick lead skin collimation was contoured over the eyes
of the nasal cavity patients to minimize electron scatter.
For the nasal cavity patients, the IMRT fields were
evenly spaced every 70 degrees. For the parotid gland
patients, the IMRT fields were arranged around the ipsi-
lateral side of body approximately every 30 degrees.
Because the ideal weighting (i.e., the ratio of photon
dose to electron dose) was not known, seven different
ratios of IMRT to electron dose were investigated. Dose
weighting was specified as the ratio of absorbed dose
from the IMRT component to that from the electron
component at the point of maximum dose in the elec-
tron beam. The following dose weights were investi-
gated: 1:0 (IMRT only), 2:1, 1:1, 1:2, 1:3, 1:4, and 0:1
(electron only). For those plans utilizing a combination
of IMRT and electrons, the electron dose component
was calculated prior to IMRT optimization to allow for
the IMRT dose component to compensate for heteroge-
neity in the electron dose distribution within the PTV.
Helical Tomotherapy Planning
Helical tomotherapy plans were constructed using
TomoTherapy Hi-Art treatment planning system (ver-
sion 3.1.2). Plan optimization was performed in beamlet
mode, where a beamlet is the fluence through a single-
leaf opening at 1 projection. There are 64 binary leaves
(0.625 cm wide at isocenter) for each projectuib, and 51
projection for each gantry rotation. During optimization,
the weights of all beamlets that intersect PTVs are
adjusted to achieve user-defined volumetric dose goals.
Plans were generated using parameters typical of clinical
delivery at the time of the study, including a 2.5-cm
nominal jaw opening and a pitch (fraction of the jaw
opening advanced by the treatment couch per
revolution) of 0.287. The planning modulation factor
(the ratio of the highest beamlet intensity to the average
intensity of all nonzero beamlets) was set to a maximum
of 3, which is the standard value used in our clinic.
TomoTherapy dose distributions were transferred to the
Pinnacle
3 system for comparison to those of the mixed-
beam technique
II.C. Plan evaluation
Helical tomotherapy and mixed beam treatments plans
were evaluated on the basis of dosimetric endpoints: tar-
get volume coverage, conformity index (CI), dose homo-
geneity index (DHI) for targets; maximum dose, mean
dose, and select dose-volume metrics for OARs. CI was
computed for the PTV using the method of Paddick
[17], given by
CI =
TV2
PIV
TV × PIV
(1)
where TVPIV represents the volume of the PTV within
the prescription isodose line, TV denotes the volume of
the PTV, and PIV denotes the volume encompassed by
the prescription isodose line. Values of CI are dimen-
sionless, have a value of 1 for an ideal treatment, and
decreases as the prescription isodose line encompasses
larger volumes outside the PTV. The dose homogeneity
index (DHI) was also computed for the PTV such that
DHI =
Dmax − Dmin
DRx
(2)
where Dmax represents the dose to 1% of the PTV,
Dmin denotes the dose to 99% of the PTV, and DRx
denotes the prescribed dose. Values of DHI are dimen-
sionless, have a value of 0 for an ideal treatment, and
increase as dose to the PTV becomes less uniform.
Helical tomotherapy and mixed beam plans were also
compared using radiobiological metrics: normal tissue
complication probability (NTCP) and tumor control
probability (TCP). NTCP values were computed using
the Lyman-Kutcher-Burman probit model [18,19]. TCP
values were computed for the PTV using the standard
Poisson dose-response model [20] assuming homoge-
neous tumor cell distribution. Additional details regard-
ing radiobiological parameters used for calculation of
NTCP and TCP can be found elsewhere [21,22].
Table 1 Relevant disease data for patients selected in the study
Patient Diagnosis Staging Disease Location Age PTV volume
1 Intermediate grade mucoepidermoid carcinoma T1N0M0 Right parotid 53 355.4 cm
3
2 Squamous cell carcinoma Unstaged Left parotid 80 197.7 cm
3
3 Moderately differentiated Squamous cell carcinoma T1-2N0M0 Left nasal septum 73 57.6 cm
3
4 Squamous cell carcinoma cT1N0M0 Left nasal septum 90 28.7 cm
3
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Figures 1 and 2 show isodose plots in the axial and
sagittal planes for patients 2 (parotid gland) and 4 (nasal
cavity) for helical tomotherapy and a selected mixed
beam plan. The PTV volume is visible as a red color-
wash contour, along with isodose lines indicating the
desired prescription dose levels. While both plans
demonstrated good coverage of the PTV, the helical
tomotherapy plans showed greater dose homogeneity
within the PTV and a better conformance of the 100%
isodose line to the PTV. The mixed beam plan showed
marked reductions in volumes of tissue encompassed by
lower isodose lines (e.g., 35, 25, and 5 Gy). Similar
results were seen in the other patients.
Figure 3 shows DVHs for patients 2 (parotid gland)
and 3 (nasal cavity) for three plans: helical tomother-
apy (solid lines), IMRT (dashed lines), and mixed
beam (dotted line, 1:4 IMRT-electron weighting). For
the both patients, the helical tomotherapy plan show
better dose uniformity in the target volume, with the
IMRT and mixed beam plans showing similar PTV
coverage and uniformity. For the parotid gland
patient, the mixed beam plan showed substantial
reduction to the spinal cord and contralateral parotid
gland over all dose intervals. For the nasal cavity
patient, the mixed beam plan showed better sparing of
the left eye, while all three plans showed similar dose
to the left lens. A detailed description of target homo-
geneity, critical structure involvement, biological
results for the plans examined in this work is now
presented.
III.A. Parotid Gland Patients
Conformity indices (CI), dose homogeneity indices
(DHI), and tumor control probabilities (TCP) for each
parotid gland patient for all plans examined in this work
are shown in Table 2. In both patients, the DHI was
best for the helical tomotherapy plan and worst for the
electron-only plan. DHI values were similar amongst
IMRT and mixed beam plans, being 0.03-0.04 larger
Figure 1 Isodose distributions for a TomoTherapy plan (left) and mixed beam plan (IMRT:electron weighting = 1:4, right) of a patient
with cancer of the parotid gland. The PTV is shown in red colorwash.
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was best for the helical tomotherapy plan, worst for the
electron-only plan, and similar among the IMRT and
mixed beam plans. The CI value in the helical
tomotherapy plan was comparable to the mixed beam
plans in patient 1, but were 0.07-0.25 greater in patient
2. Of note was that the introduction of a small IMRT
component into the electron plan (e.g., the 1:4 mixed
beam plan) restored the CI and DHI to values compar-
able to the IMRT plan, i.e., adding additional IMRT was
of no benefit. Despite the differences in CI and DHI, the
TCP values were greater than 98.4% for all plans and
less than 1% variation amongst the different plans, with
the exception of the electron-only plan for Patient 1.
Selected dose metrics and normal tissue complication
probabilities (NTCP) for critical structures are shown in
Table 2 for all plans. In both patients, mean dose to the
contralateral parotid and the corresponding NTCP was
lowest in the electron-only plan. Mean dose and NTCP
for the contralateral parotid were largest in the IMRT
plan (7.3 Gy and 7.9%, respectively) in Patient 1, and in
the helical tomotherapy plan (13.2 Gy and 14.4%,
respectively) in Patient 2. In general, mean dose and
NTCP for the contralateral parotid decreased as electron
weighting increased. Maximum dose to the spinal cord
was comparable amongst all plans, and the correspond-
ing NTCP did not exceed 0.6% in any plan. Maximum
dose to the eyes was greatest in the helical tomotherapy
plans (range: 6.9 - 12 Gy), with the exception of the
ipsilateral eye in Patient 2.
III.B. Nasal Cavity Patients
CI, DHI, TCP for each nasal cavity patient are shown in
Table 3 for all plans. As with the parotid gland patients,
the DHI was best for the helical tomotherapy plan and
worst for the electron-only plan. DHI values were simi-
lar amongst IMRT and mixed beam plans, and were
0.02-0.06 larger than in the helical tomotherapy plans.
CI was comparable among all plans in Patient 3, and
best in the helical tomotherapy plan in Patient 4. As
Figure 2 Isodose distributions for a TomoTherapy plan (left) and mixed beam plan (IMRT:electron weighting = 1:4, right) of a patient
with cancer of the parotid gland. The PTV is shown in red colorwash.
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Page 5 of 10was noted previously, the introduction of a small IMRT
component into the electron plan restored the CI and
DHI to values comparable to the IMRT plan. TCP
values were greater than 99.9% or higher for all plans.
Selected dose metrics and NTCP values for critical
structures are shown in Table 3 for all plans. In both
patients, maximum dose to the lenses of the eyes was
lowest in the electron-only plans (1.8 - 7.8 Gy).
Maximum dose to the eyes was also lowest in the elec-
tron-only plans, with the exception of the left eye and
Patient 4. The IMRT and mixed beam plans tended to
show similar normal tissue doses. Helical tomotherapy
plans showed the highest lens and eye doses in Patient
3, and doses lower than or comparable to the mixed
beam plans in Patient 4. NTCP values did not exceed
2.8% in any plan.
Figure 3 DVHs for (a) patient 2 (parotid gland) and (b) patient 3 (nasal cavity) from helical tomotherapy, IMRT, and mixed beam (1:4
IMRT-electron weighting). Abbreviations: PTV = planning target volume; Cont. = contralateral; L. = left.
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Page 6 of 10Table 2 Conformity index (CI), dose homogeneity index (DHI), tumor control probability (TCP), normal tissue
complication probably (NTCP) and normal tissue dose metrics for the parotid gland patients.
Patient Plan
(IMRT:e)
PTV Normal Tissues
CI DHI TCP
(%)
Cont. Parotid Spinal Cord Cont. Eye Ips. Eye
Dmean
(Gy)
NTCP
(%)
Dmax
(Gy)
NTCP
(%)
Dmax
(Gy)
Dmax
(Gy)
1 HT 0.85 0.06 98.5 6.0 6.8 43.2 0.3 6.9 9.1
1:0 0.84 0.10 98.6 7.3 7.9 45.3 0.5 2.9 4.4
2:1 0.85 0.09 98.7 6.7 7.3 46.6 0.6 3.2 4.0
1:1 0.80 0.10 98.6 6.9 7.5 48.1 0.5 3.6 4.1
1:2 0.83 0.09 98.7 5.0 6.0 43.8 0.4 3.5 3.7
1:3 0.82 0.09 98.7 4.9 6.0 44.2 0.4 3.5 3.7
1:4 0.81 0.10 98.7 4.9 5.9 43.9 0.3 3.6 3.8
0:1 0.66 0.27 95.6 3.4 4.9 45 0.4 3.6 3.9
2 HT 0.77 0.02 100 13.2 14.4 41.2 0.4 12 11.9
1:0 0.65 0.06 100 8.2 8.6 43.3 0.3 7.6 11.1
2:1 0.65 0.06 100 6.0 6.8 39 0.1 6.2 13.5
1:1 0.70 0.05 100 5.1 6.1 37.2 < 0.1 4.7 13.7
1:2 0.52 0.06 100 4.0 5.3 36.1 < 0.1 3.8 14.1
1:3 0.60 0.06 100 3.5 5.0 35.8 < 0.1 3.0 14.0
1:4 0.59 0.05 100 3.1 4.8 35.6 < 0.1 3.7 16.0
0:1 0.18 0.18 99.7 1.1 3.7 30.7 < 0.1 1.6 14.6
Beam weightings indicate the ratio of IMRT-to-electron dose of the treatment plans. Abbreviations: PTV = planning target volume; Cont. = contralateral; Ips. =
ipsilateral; R. = right; L. = left.
Table 3 Conformity index (CI), dose homogeneity index (DHI), tumor control probability (TCP), normal tissue
complication probably (NTCP) and normal tissue dose metrics for the nasal cavity patients.
Patient Plan
(IMRT:e)
PTV Normal Tissues
CI DHI TCP
(%)
L. Lens R. Lens L. Eye R. Eye
Dmean
(Gy)
NTCP
(%)
Dmax
(Gy)
NTCP
(%)
Dmax
(Gy)
Dmax
(Gy)
3 HT 0.80 0.07 100 8.0 0.3 14.9 2.8 40.5 37.6
1:0 0.76 0.09 100 8.9 0.6 9.9 0.6 36.0 39.2
2:1 0.84 0.09 100 11.0 2.2 9.6 0.8 32.1 33.2
1:1 0.85 0.10 100 10.6 2.6 9.8 0.9 32.3 33.8
1:2 0.85 0.11 100 8.8 0.6 8.0 0.4 27.5 32.3
1:3 0.83 0.09 100 6.6 0.3 8.5 0.4 28.4 33.5
1:4 0.82 0.10 100 7.6 0.6 9.2 0.5 30.2 33.0
0:1 0.75 0.29 99.9 4.3 0.1 7.8 0.2 22.7 30.0
4 HT 0.80 0.04 100 2.9 0.1 3.5 0.1 6.4 8.6
1:0 0.75 0.14 100 3.5 0.1 4.0 0.1 22.0 9.1
2:1 0.60 0.07 100 2.8 0.1 4.0 0.1 12.3 9.1
1:1 0.72 0.08 100 3.3 0.1 4.4 0.1 12.7 8.7
1:2 0.68 0.08 100 3.3 0.1 3.9 0.1 12.0 10.1
1:3 0.79 0.10 100 3.6 0.1 3.9 0.1 10.1 7.8
1:4 0.73 0.09 100 2.7 0.1 3.7 0.1 10.6 9.7
0:1 0.57 0.19 100 1.8 < 0.1 2.3 < 0.1 17.1 8.4
Beam weightings indicate the ratio of IMRT-to-electron dose of the treatment plans. Abbreviations: PTV = planning target volume; Cont. = contralateral; Ips. =
ipsilateral; R. = right; L. = left.
Blasi et al. Radiation Oncology 2011, 6:178
http://www.ro-journal.com/content/6/1/178
Page 7 of 10IV. Discussion
In this study we compared helical tomotherapy and
IMRT-electron mixed beam plans of various weightings
(including IMRT-only and electron-only) for superficial
head and neck cancers of the parotid gland and the
nasal cavity. Helical tomotherapy plans showed dose
conformity and homogeneity in the PTV that was equal
to or better than IMRT and mixed beam plans. Elec-
tron-only plans tended to show the lowest doses to nor-
mal tissues, particularly in the parotid gland patients
where critical structures were located further from the
PTV, but with markedly worse dose conformity and
homogeneity in the target volume than in the other
plans. However, adding a 20% IMRT dose fraction (e.g.,
IMRT:electron weighting = 1:4) to the electron plan
restored target conformity and homogeneity to values
equal to or better than the IMRT-only plans and com-
parable to helical tomotherapy plans, while only slightly
increasing normal tissue dose. These results suggest that
(1) IMRT-electron mixing offers some dosimetric advan-
tages over IMRT or helical tomotherapy for target
depths do not exceed the useful range of the electron
beam and (2) only a small (20% in this study) compo-
nent of IMRT is needed to restore dose homogeneity to
the target volume in an electron plan.
The results of this work are consistent with the stu-
dies from Mu et al. [14] and Chan et al. [15,16] that
investigated the use of combining unmodulated electron
beams and IMRT for head and neck targets. Both stu-
dies also reported that the mixed beam approach could
achieve dose homogeneity and normal tissue sparing
comparable to IMRT plans. However, our study further
indicated that mixed beams of electrons and IMRT can
produce dosimetric results comparable to helical
tomotherapy, which has generally been shown to pro-
vide superior dosimetric results for head and neck can-
cers compared with IMRT alone. We believe the
improvement in dosimetric results can be attributed to
our approach of allowing the IMRT optimization to
account for the electron dose component during treat-
ment planning.
The results of this work are further expected to be
independent of the electron dose calculation algorithm
employed. In this work, the electron beam dose was cal-
culated using the pencil beam algorithm (PBA), which
has been shown to produce significant errors in regions
of tissue heterogeneity [23,24]. While use of a different
electron dose calculation algorithm may change the
shape of the electron dose distribution, these dosimetric
changes can be accounted for with the IMRT compo-
nent so long as it is optimized on top of the electron
dose. To verify our assertion, the mixed beam plan (1:4
IMRT-electron weighting) for patient 3 was reoptimized
following calculation of the electron beam dose using
the pencil beam redefinition algorithm (PBRA), which
has been shown to significantly improve electron dose
calculation accuracy in heterogeneous phantoms [25,26].
As shown in Figure 4, differences between plans opti-
mized and calculated with the PBA and PBRA are
negligible.
Mixed beam therapy has some practical concerns
when compared with IMRT or helical tomotherapy that
need consideration. First, clinical implementation of
mixed beam therapy using conventional, existing techni-
ques requires additional setup time. Delivery of the elec-
tron component requires use of an electron applicator
Figure 4 Transverse view of the dose distribution taken through the PTV (shown in red colorwash) (a) and DVHs (b) for the mixed
beam (1:4 IMRT-electron weighting) of patient 3 where the electron dose has been calculated with the pencil beam redefinition
algorithm (PBRA). The mixed beam plan calculated with the PBRA showed negligible differences compared with the original plan, which was
calculated using the electron PBA. Abbreviations: PTV = planning target volume; L. = left.
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delivery of the IMRT component requires removal of
the electron applicator and is typically treated using an
SAD technique. As such, radiation technologists are
required to enter the treatment room to adjust the
accelerator hardware and reset the patient couch prior
to delivery of the next modality. Future work should
investigate the use of conventional photon MLCs to
shape and deliver electron fields, which would eliminate
the need for the radiation technologist to enter the
room between modality deliveries. Furthermore, because
the IMRT component of the mixed beam plan was used
to compensate for the heterogeneity of the electron dose
distribution, the IMRT component was also heteroge-
neous. Dose gradients within a given modality could
introduce hot or cold spots in composite dose distribu-
tion in the presence of any misalignment between mod-
ality deliveries. Finally, use of current commercial
electron pencil beam algorithms for mixed beam plan-
ning must be validated and, as such, our group is cur-
rently investigating dosimetric verification of mixed
beam plans [27].
Recently, electron conformal therapy using a variable
wax bolus has become widely available [28,29], which
can produce dose distributions superior to open electron
fields. Future work should attempt to investigate the use
of a variable thickness wax bolus, which should even
further reduce normal tissue dose with comparable dose
homogeneity in the mixed beam plans.
V. Conclusion
Our results suggest that mixed beam treatments offer
dosimetric advantages over IMRT or helical tomother-
apy for target depths that do not exceed the useful
range of the electron beam. Adding a small IMRT com-
ponent (e.g., IMRT:electron weighting = 1:4) to electron
beam plans markedly improved target dose homogeneity
and conformity for the cases examined in this study.
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